



New patent approvals for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has during the last months received four additional patent approval notifications. The Indian patent office Intellectual Property India has reported that Episurf has received two new granted patents in India. One is related to implant materials and coatings, while the other is related to Episurf's damage visualisation process for surgical pre-planning and individualised medical device design. The Australian patent office IP Australia has issued a notice of acceptance for a patent related to the implant-specific drill used for Episurf's implant technology. Lastly, the Companies and Intellectual Property Commission of South Africa has granted Episurf its first ever patent in South Africa. That patent covers a system for customising an implant for treatment of damage in an anatomical joint.

"As we take new steps towards new global markets, we also take care to protect our technology. While we are at an early stage in Australia and South Africa, India is currently a highly prioritised country for Episurf. A number of surgeries with Episurf's Episealer® implants have taken place there during this year, and the increased patent protection there is appreciated to strengthen our position in this highly interesting market", comments Katarina Flodström, COO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 28 November 2023.